By contrast, the recently introduced GLP-1 class obesity drugs overcome the shortcomings of earlier medications and, beyond simple weight loss, are demonstrating diverse benefits in improving complications, such as reducing cardiovascular disease risk, alleviating sleep apnea, and easing metabolic dysfunctionassociated steatohepatitis (MASH). The issue is that patients in urgent need of obesity treatment are not benefiting from these drugs
This study of more than 16,400 subjects found a 27% increased rate of hospitalization for acute HF after approximately 2 years of saxagliptin therapy ( P = .007)
Both medicines are administered as subcutaneous injections, typically once weekly, and are still undergoing large-scale clinical trials
In vitro, OGD-induced ferroptosis was ameliorated by GSH, which restored cell proliferation, reduced oxidative stress, and upregulated ferroptosis defense factors